Skip to main content
SpringerLink
Log in

Use of Drugs in Uremia and Dialysis

  • Chapter
Therapy of Renal Diseases and Related Disorders

  • 130 Accesses

Abstract

The presence of abnormal kidney function predisposes affected individuals to adverse effect from drugs (1–3). Persons with kidney disease receive drugs for the same variety of day to day elective or emergency medical problems as do other persons in the general population. In addition, those with advanced renal disease receive drugs for the management of complications of the renal failure. Persons with systemic diseases associated with significant kidney involvement frequently require drug treatment for a variety of extrarenal medical and/or surgical problems. Finally, individuals developing acute renal failure are often receiving or are about to receive, one or more drugs in the course of treatment of the precipitating illness. Thus, clinicians are frequently involved with the use of many different drugs in patients with varying degrees of renal dysfunction, where the potential for adverse drug-disease interactions is formidable.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Smith JW, Seidl LG, Cluff LE: Studies on the epidemiology of adverse drug reactions. V: Clinical factors influencing susceptibility. Ann Intern Med 65: 629–640, 1966.

    PubMed  CAS  Google Scholar 

  2. Gray RK, Adams LL, Fallon HJ: Short term intensive surveillance of adverse drug reactions. J Clin Pharmacol 13:61–67, 1973.

    CAS  Google Scholar 

  3. Levy M, Lipshitz M, Eliakin M: Hospital admissions due to adverse drug reactions. Am J Med Sci 277:49–56, 1979.

    PubMed  CAS  Google Scholar 

  4. Harvey SC: Gastric antacids and digestants. In: Oilman AG, Goodman LS, Gilman A (eds) The pharmacologic basis of therapeutics. New York, Macmillan, 1980, pp 988–1001.

    Google Scholar 

  5. Lowenthal DT, Briggs WA, Gibson TP et al: Pharmacokinetics of oral propranolol in chronic renal disease. Clin Pharmacol Ther 16 (5): 761–768, 1974.

    PubMed  CAS  Google Scholar 

  6. Gibson TP, Giacomini KM, Briggs WA et al: Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient. Clin Pharmacol Ther 27 (5): 665–670, 1980.

    PubMed  CAS  Google Scholar 

  7. Reidenberg MM: The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. Am J Med 62:466–470, 1977.

    PubMed  CAS  Google Scholar 

  8. Reidenberg MM: Renal function and drug action, Philadelphia, WB Saunders Co, 1971.

    Google Scholar 

  9. Lichter M, Black M, Arias IM: The metabolism of anti-pyrine in patients with chronic renal failure. J Pharmacol Exp Ther 187: 612–619, 1973.

    PubMed  CAS  Google Scholar 

  10. Reidenberg MM, Odar-Cederiof I, von Bahr C et al: Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med 285:264–267, 1971.

    PubMed  CAS  Google Scholar 

  11. Reidenberg MM, Lowenthal DT, Briggs WA, Gasparo M: Pentobarbital elimination patients with poor renal function. Clin Pharmacol Ther 20:67–71, 1976.

    PubMed  CAS  Google Scholar 

  12. Lowenthal DT: Pharmacokinetics of propranolol, quinidine, procainamide and lidocaine in chronic renal disease. Am J Med 62: 532–538, 1977.

    PubMed  CAS  Google Scholar 

  13. Cockroft DW, Gauh MH: Prediction of creatinine elearanee from serum creatinine. Nephron 16: 31–41, 1976.

    Google Scholar 

  14. Bjomsson TD: Use of serum creatinine concentrations to determine renal function. Clin Pharmacokinet 1: 135–155, 37. 1976.

    Google Scholar 

  15. Teschan PE, Ginn HE: The nervous system. In: Massry SA, Sellers AL (eds). Clinical aspects of uremia and dialysis. Springfield, III, 1980, pp 3–33.

    Google Scholar 

  16. Teehan BP, Maher JF, Carey JJH et al: Acute ethchlorvynal (Placidyl®) intoxication. Ann Intern Med 72:875–882, 1970.

    PubMed  CAS  Google Scholar 

  17. Tozer TN, Witt LD, Gee L: Evaluation of hemodialysis for ethchlorvynol (Placidyl) overdose. Am J Hosp Pharm 31:986–989, 1974.

    PubMed  CAS  Google Scholar 

  18. Lynn RI, Honig CL, Jatlow PI, Kliger AS: Resin hemoperfusion for treatment of ethchlorvynol overdose. Ann Intern Med 91:549–553, 1979.

    PubMed  CAS  Google Scholar 

  19. Douglas JF, Ludwig BJ, Smith N: Studies on the metabolism of meprobamate. Proc Soc Exp Biol Med 112: 436–42. 438, 1963.

    Google Scholar 

  20. Mouton DE, Cohen RJ, Barrett O JR: Meprobamate poisoning: Successful treatment with peritoneal dialysis. Am J Med Sci 253: 706–709, 1967.

    PubMed  CAS  Google Scholar 

  21. Lobo PI, Spyker D, Surratt P, Westerveh FB Jr: Use of hemodialysis in mephrobamate overdosage. Clin Nephrol 7: 73–75, 1977.

    PubMed  CAS  Google Scholar 

  22. Owens AH, Marshall EK Jr: Further studies on the metabolic fate of chloral hydrate and trichloroethanol. Johns Hopkins Hosp Bull 97: 320–326, 1955.

    CAS  Google Scholar 

  23. Loeser WD, Fisher CJ, Boulis O: Forty-three dialyses in a community hospital. J Am Med Assoc 192:809–812, 1965.

    Google Scholar 

  24. Mark LC: Pharmacokinetics of barbiturates. In: Matthew H (ed). Acute barbiturate poisoning. Amsterdam, Holland, Excerpta Medica, 1971, pp 75–83.

    Google Scholar 

  25. Hahn TJ, Birge SJ, Scharp CR, Avioli LV: Phenobarbital- induced alterations in vitamin D metabolism. J Clin Invest 51: 741–748, 1972.

    PubMed  CAS  Google Scholar 

  26. Setter JO, Maher JF, Schreiner GE: Barbiturate intoxication. Arch Intern Med 117: 224–236, 1966.

    PubMed  CAS  Google Scholar 

  27. Kennedy AC, Briggs JD, Young N et al.: Successful treatment of three cases of very severe barbiturate poisoning. Lancet 1: 995–998, 1969.

    PubMed  CAS  Google Scholar 

  28. Decker WJ, Combs HF, Treuting JJ, Banez RJ: Dialysis of drugs against activated charcoal. Toxicol Appl Pharmacol 18: 573–578, 1971.

    PubMed  CAS  Google Scholar 

  29. Hill JB, Palcia FL, McAdams JL et al: Efficacy of activated charcoal hemoperfusion in removing lethal doses of barbiturates and salicylate from the blood of rats and dogs. Clin Chem 22: 754–760, 1976.

    PubMed  CAS  Google Scholar 

  30. Berman LB, Vogelsang P: Removal rates for barbiturates using two types of peritoneal dialysis. N Engl J Med 270: 77–80, 1964.

    PubMed  CAS  Google Scholar 

  31. Bloomer HA: Limited usefulness of alkaline diuresis and peritoneal dialysis in pentobarbital intoxication. N Engl J Med 272: 1309–1313, 1965.

    PubMed  CAS  Google Scholar 

  32. Campion DS, North JDK: Effect of protein binding of barbiturates on their rate of removal during peritoneal dialysis. J Lab Clin Med 66: 549–563, 1965.

    PubMed  CAS  Google Scholar 

  33. Cameron JS, Read JF, Ogg CS et al: Accumulation of barbitone in patients on regular hemodialysis. Lancet 1: 912–914, 1970.

    PubMed  CAS  Google Scholar 

  34. Schwartz MA, Postma E, Gaut Z: Biological half-life of chlordiazepoxide and its metabolite, demoxepam, in man. J Pharm Sci 60: 1500–1503, 1971.

    PubMed  CAS  Google Scholar 

  35. Kaplan SA, Jack ML, Alexander K, Weinfeld RE: Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. J Pharm Sci 62: 1789–1796, 1973.

    PubMed  CAS  Google Scholar 

  36. Kaplan SA, deSilva JAF, Jack ML et al: Blood level profile in man following chronic oral administration of flurazepam hydrochloride. J Pharm Sci 62: 1932–1935, 1973.

    PubMed  CAS  Google Scholar 

  37. Cruz IA, Cramer NC, Parrish AE: Hemodialysis in chlordiazepoxide toxicity. J Am Med Assoc 202: 438–440, 1967.

    CAS  Google Scholar 

  38. Knowles JA, Ruelius HW: Absorption and excretion of 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one (Oxazepam) in humans. Aizneim forsch 22: 687–692, 1972.

    CAS  Google Scholar 

  39. Huxtable RF, Landwirth J: Diphenhydramine poisoning treated by exchange transfusion. Am J Dis Child 106: 496–500, 1973.

    Google Scholar 

  40. Korczyn AD: The major tranquilizers. In: Dukes MNG (ed), Meyler’s side effects of drugs. 9th edition. Amsterdam, Holland, Excerpta Medica, 1980, pp 76–89.

    Google Scholar 

  41. Rabinowitz P, Friedman IA: Drug-induced lactation in uremia. J Clin Endocrin Metab 21: 1489–1493, 1961.

    CAS  Google Scholar 

  42. Murphy KJ: Uraemic accentuation of chorpromazine pigmentation. Med J Aust 2: 1228–1229, 1966.

    PubMed  CAS  Google Scholar 

  43. Avram MM, McGinn JT: Extracorporeal Hemodialysis in phenothiazine overdosage. J Am Med Assoc 197: 182–183, 1966.

    Google Scholar 

  44. Marcucci F, Mussini E, Airoldi L et al: Analytical and pharmacokinetic studies on butyrophenones. Clin Chim Acta 34: 321–332, 1971.

    PubMed  CAS  Google Scholar 

  45. Edelstein EL: Antidepressant drugs. In: Dukes MNG (ed), Meyler’s side effects of drugs, 9th edition. Amsterdam, Holland, Excerpta Medica, 1980, pp 21–42.

    Google Scholar 

  46. Spiker DO, Weiss AN, Chang SS et al.: Tricyclic antidepressant overdose: Clinical presentation and plasma levels. Clin Pharmacol Ther 18: 539–546, 1975.

    PubMed  CAS  Google Scholar 

  47. Bailey RR, Sharman JR, O’Rourke J, Buttimore AL: Haemodialysis and forced diuresis for tricyclic antidepressant poisoning. Br Med J 4: 230–231, 1974.

    PubMed  CAS  Google Scholar 

  48. Asbach HW, Mohring K, Holz F et al: Haemodialysis in imipramine poisoning? Klin Wochenschr 54: 53–87, 1976.

    Google Scholar 

  49. Treitman P: Desipramine poisoning. JAMA 220: 861, 864, 1972.

    Google Scholar 

  50. Hawthorne JW, Marcus AM, Kaye M: Management of massive imipramine overdose with mannitol and artificial dialysis. N Engl J Med 268: 33–36, 1963.

    Google Scholar 

  51. Trautner EM, Morris R, Noack CH, Gershon A: The excretion and retention of ingested lithium and its effect on the ionic balance of man. Med J Aust 2: 280–291, 1955.

    Google Scholar 

  52. Cox M, Singer I: Lithium and water metabolism. Am J Med 59: 153–157, 1975.

    PubMed  CAS  Google Scholar 

  53. Amdisen A, Schou M: Lithium. In: Dukes MNG (ed), Meyler’s side effects of drugs. 9th edition. Amsterdam, Holland, Excerpta Medica, 1980, pp 43–50.

    Google Scholar 

  54. Perez GO, Oster JR, Vaamonde CA: Incomplete syndrome of renal tubular acidosis induced by lithium carbonate. J Lab Clin Med 86: 386–394, 1975.

    PubMed  CAS  Google Scholar 

  55. Hestbech J, Hansen HE, Amdisen A, Olsen S: Chronic renal lesions following long-term treatment with lithium. Kidney Int 12:205–213, 1977.

    Google Scholar 

  56. Amdisen A, Sjoldborg H: Hemodialysis for lithium poisoning. Lancet 2: 213, 1969.

    PubMed  CAS  Google Scholar 

  57. Wilson JHP, Donker AJM, Van der Hem GK, Wientjes J: Peritoneal dialysis for lithium poisoning. Br Med J 2: 749–750, 1971.

    PubMed  CAS  Google Scholar 

  58. Lowenthal DT, Briggs WA, Levy G: Kinetics of salicylate elimination by anephric patients. J Clin Invest 54: 1221–1226, 1974.

    PubMed  CAS  Google Scholar 

  59. Bennett WM, Muther RS, Parker RA et al: Drug therapy in renal failure: dosing guidelines for adults. Part I. Antimicrobial agents, analgesics. Ann Intern Med 93: 62–89, 1980.

    PubMed  CAS  Google Scholar 

  60. Oie S, Lowenthal DT, Briggs WA, Levy G: Effect of hemodialysis on kinetics of acetaminophen elimination by anephric patients. Clin Pharmacol Ther 18: 680–686, 82. 1976.

    Google Scholar 

  61. Giacomini KM, Gibson TP, Levy G: Plasma protein binding of d-propoxyphene in normal subjects and anephric patients. J Clin Pharmacol 18: 106–109, 1978.

    PubMed  CAS  Google Scholar 

  62. Giacomini KM, Gibson TP, Levy G: Effect of hemodialysis on propoxyphene and norpropoxyphene concentrations in blood of anephric patients. Clin Pharmacol Ther 27: 508–514, 1980.

    PubMed  CAS  Google Scholar 

  63. Olsen GD, Bennett WM, Porter GA: Morphine and Phenytoin binding to plasma proteins in renal and hepatic failure. Clin Pharmacol Ther 17: 677–684, 1975.

    PubMed  CAS  Google Scholar 

  64. Don HF, Dieppa RA, Taylor P: Narcotic analgesics in anuric patients. Anesthesiology 42:745–747, 1975.

    Google Scholar 

  65. Szeto HH, Inturrisi CE, Houde R et al: Accumulation of normeperidine, an active metabolite of meperidiine, in patients with renal failure or cancer. Ann Intern Med 86: 738–741, 1977.

    PubMed  CAS  Google Scholar 

  66. Bennett WM, Muther RS, Parker RA et al: Drug therapy in renal failure: Dosing guidelines for adults. Part II. Sedatives, hypnotics and tranquilizers; cardiovascular, antihypertensive, and diuretic agents; miscellaneous agents. Ann Intern Med 3: 286–325, 1980.

    Google Scholar 

  67. Stein G, Kunze M, Zaumseil J, Traeger A: Zur Pharmakokinetik von indomethazin und indomethazin-metaboliten bei wiederholter applikation an nierengesunden und nierengeschadigten patieten. Internat J Clin Pharmacol Biopharm 15: 470–473, 1977.

    CAS  Google Scholar 

  68. Helleberg L: Clinical pharmacokinetics of indomethacin. Clin Pharmacokinetics 6: 245–258, 1981.

    CAS  Google Scholar 

  69. Dunn MJ, Zambraski E: Renal effects of drugs that inhibit prostaglandin synthesis. Kidney Int 18: 609–622, 1980.

    PubMed  CAS  Google Scholar 

  70. Epstein M, Lifschitz MD: Volume status as a determinant of the influence of renal PGE on renal function. Nephron 25: 157–159, 1980.

    PubMed  CAS  Google Scholar 

  71. Galler M, Folkert V, SchlondorffD: Reversible acute renal insufficiency and hyperkalemia following indomethacin therapy. JAMA 246: 154–155, 1981.

    PubMed  CAS  Google Scholar 

  72. Goldszer RC, Coodley EL, Rosner MJ et al: Hyperkalemia associated with indomethacin. Arch Intern Med 141: 802–804, 1981.

    PubMed  CAS  Google Scholar 

  73. Kimberly RP, Bowden RE, Keiser HR, Plötz PH: Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. Am J Med 64: 804–807, 1978.

    PubMed  CAS  Google Scholar 

  74. Tan SY, Burton M: Hyporeninemic hypoaldosteronism. An overiooked cause of hyperkalemia. Arch Intern Med 141: 30–33, 1981.

    PubMed  CAS  Google Scholar 

  75. Kimberly RP, Sherman RL, Mouradian J, Lockshin MD: Apparent acute renal failure associated with therapeutic aspirin and ibuprofen administration. Arth Rheum 22: 281–285, 1979.

    CAS  Google Scholar 

  76. Cartwright KC, Trotter TL, Cohen ML: Naproxen nephrotoxicity. Arizona Med 36: 124–126, 1979.

    PubMed  CAS  Google Scholar 

  77. Kimberly RP, Brandstetter RD: Exacerbation of phenylbutazone-related renal failure by indomethacin. Arch intern Med 138: 1711–1712, 1978.

    PubMed  CAS  Google Scholar 

  78. Curt GA, Kaldany A, Whitley LG et al: Reversible rapidly progressive renal failure with nephrotic syndrome due to fenoprofen calcium. Ann Intern Med 92: 72–73, 1980.

    PubMed  CAS  Google Scholar 

  79. Wendland M, Wagoner RD, Holley KE: Renal failure associated with fenoprofen. Mayo Clin Proc 55: 103–107, 1980.

    PubMed  CAS  Google Scholar 

  80. Brezin JH, Katz SM, Schwartz AB, Chinitz JL: Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 302: 1271–1273, 1979.

    Google Scholar 

  81. Handa SP: Renal effects of fenoprofen. Ann Intern Med 93: 508–509, 1980.

    Google Scholar 

  82. Lorch J, Lefavour G, Davidson H, Cortell S: Renal effects of fenoprofen. Ann Intern Med 93: 509, 1980.

    Google Scholar 

  83. Register RF: Nephrotic syndrome and renal failure associated with use of nonsteroidal anti-inflammatory drugs. J Tenn Med Assoc 73: 709–711, 1980.

    Google Scholar 

  84. Brandstetter RD, Mar DD: Reversible oliguric renal failure associated with ibuprofen treatment. Brit Med J 2: 1194–1195, 1978.

    PubMed  CAS  Google Scholar 

  85. Herrick RT: Reversible renal failure due to ibuprofen. J Med Assoc State Ala 50: 20, 1980.

    PubMed  CAS  Google Scholar 

  86. Katz SM, Capaldo R, Everts EA et al: Tolmetin - association with reversible renal failure and acute interstitial nephritis. JAMA 246: 243–245, 1981.

    PubMed  CAS  Google Scholar 

  87. Chatteijee GP: Nephrotic syndrome induced by tolmetin. JAMA 246: 1589, 1981.

    Google Scholar 

  88. Greenstone M, Hartley B, Gabriel R, Bevan G: Acute nephrotic syndrome with renal failure after phenylbutazone. Brit Med J 282: 950–951, 1981.

    CAS  Google Scholar 

  89. Husseri FE, Lange RK, Kantrow CM: Renal papillary necrosis and pyelonephritis accompanying fenoprofen therapy. JAMA 242: 1896–1898, 1979.

    Google Scholar 

  90. DeFronzo RA, Andres R, Edgar P, Walker WG: Carbohydrate metabolism in uremia: A review. Medicine 52: 469–481, 1973.

    PubMed  CAS  Google Scholar 

  91. Rabkin R, Simon NM, Steiner S, Colwell JA: Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med 282: 182–187, 1970.

    PubMed  CAS  Google Scholar 

  92. Bennett WM, Muther RS, Parker RA et al: Drug therapy in renal failure: dosing guidelines for adults. Ann Intern Med 93: 286–325, 1980.

    PubMed  CAS  Google Scholar 

  93. Stowers JM, Borthwick LJ: Oral hypoglycaemic drugs: Clinical pharmacology and therapeutic use. Frugs 14: 41–56, 1977.

    CAS  Google Scholar 

  94. Graw RG, Clarke RR: Chlorpropamide intoxication- treatment with peritoneal dialysis. Pediatrics 45: 106–109, 1970.

    PubMed  CAS  Google Scholar 

  95. Skoutakis VA, Black WD, Acchiardo SR, Wood GC: Peritoneal dialysis inthe treatment of acetohexamide-induced hypoglycemia. Am J Hosp Pharm 34: 68–70, 1977.

    PubMed  CAS  Google Scholar 

  96. Mudge GH: Water and osmotic diuretics. In: Gilman AG, Goodman LS, Gilman A (eds). The pharmacologic basis of therapeutics. New York, MacMillan, 1980, pp 893–896.

    Google Scholar 

  97. Mudge GH: Benzothiadiazides. In: Gilman AG, Goodman LS, Gilman A (eds). New York, MacMillan, 1980, pp 899–903.

    Google Scholar 

  98. Karim A: Spironolactone: Disposition, metabolism, pharmacodynamics and bioavailability. Drug Metab Rev 8: 151–188, 1978.

    PubMed  CAS  Google Scholar 

  99. Knaut H, Schnippenkotter I, Wais U et al: Diuretic activity and renal elimination of triamterene and its metabolites in renal insufficiency. Kidney Int 13: 528–529, 1978.

    Google Scholar 

  100. Allison ME, Kennedy AC: Diuretics in chronic renal disease: A study of high dosage furosemide. Clin Sei 41:171 –123. 187, 1971.

    Google Scholar 

  101. Fairiey KF, Laver M: High dose furosemide in chronic renal failure. Postgrad Med J 47 (Suppl): 40–41, 1971.

    Google Scholar 

  102. Cutler RE, Forrey Aw, Christopher TG, Kimpel BM: Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. Clin Pharmacol Ther 15: 588–596, 1974.

    PubMed  CAS  Google Scholar 

  103. Huang CM, Atkinson AJ, Levin NW et al: Pharmacokinetics of furosemide in advanced renal failure. Clin Pharmacol Ther 16: 659–666, 1974.

    PubMed  CAS  Google Scholar 

  104. Andreason F, Hansen HE, Mikkelsen E: Pharmacokinetics of furosemide in anephric patients and in normal subjects. Eur J Clin Pharmacol 13: 41–48, 1978.

    Google Scholar 

  105. Cooperman LB, Rubin IL: Toxicity of ethacrynic acid and furosemide. Am Heart J 85: 831–834, 1973.

    PubMed  CAS  Google Scholar 

  106. Brown RD: Comparison of the cochlear toxicity of sodium ethacrynate, furosemide, and the cysteine adduct of sodium ethacrynate in cats. Toxicol Appl Pharmacol 31: 270–282, 1975.

    PubMed  CAS  Google Scholar 

  107. Dargie HJ, Allison MEM, Kennedy AC, Gray MJB: High dose metolazone in chronic renal failure. Br Med J 4: 196–198, 1972.

    PubMed  CAS  Google Scholar 

  108. Tilstone WJ, Dargie H, Dargie EN et al: Pharmacokinetics of metaolazone in normal subjects and in patients with caardiac or renal failure. Clin Pharmacol Ther 131. 16: 322–329, 1974.

    Google Scholar 

  109. Black WD, Shiner PT, Roman J: Severe electrolyte disturbances associated with metolazone and furosemide. South 132. Med J 71: 380–381, 1978.

    CAS  Google Scholar 

  110. Jelliffe RW, Buell J, Kalaba R et al: An improved method of digitoxin therapy. Ann Intern Med 72:453–464, 1970.

    Google Scholar 

  111. Storstein L: Studies on digitalis. V: The influence of impaired renal function, hemodialysis, and drug interaction on serum protein binding of digitoxin. Clin Pharmacol Ther 20: 6–14, 1976.

    PubMed  CAS  Google Scholar 

  112. Rasmussen K, Jervell J, Storstein L, Gjerdrum K: Digitoxin kinetics inpatients with impaired renal function. Clin Pharmacol Ther 13:6–14, 1972. 136.

    Google Scholar 

  113. Jelliffe RW, Brooker G: A nomogram for digoxin therapy. Am J Med 57: 63–68, 1974.

    PubMed  CAS  Google Scholar 

  114. Jelliffe RW: An Improved method of digoxin therapy. Ann Intern Med 69:703–717, 1968.

    Google Scholar 

  115. Gault MH, Jeffrey JR, Chirito E, Ward LL: Studies of digoxin dosage, kinetics and serum concentrations in renal failure and review of the literature. Nephron 17: 161–187, 138. 1976.

    Google Scholar 

  116. Doherty JE: The clinical pharmacology of digitalis glycosides: A review. Am J Med Sci 255: 382–414, 1968.

    PubMed  CAS  Google Scholar 

  117. Jusko WJ, Zsefler SJ, Goldfard AL: Pharmacokinetic design of digoxin dosage regimens in relation to renal function. J Clin Pharmacol 14: 525–535, 1974.

    PubMed  CAS  Google Scholar 

  118. Ackerman GL, Doherty JE, Flanigan WJ: Peritoneal dialysis and hemodialysis of tritiated digoxin. Ann Intern Med 67: 718, 1967.

    PubMed  CAS  Google Scholar 

  119. Marbury T, Mahoney J, Juncos L et al: Advanced digoxin toxicity in renal failure: Treatment with charcoal hemoperfusion. South Med J 72: 279–286, 1979.

    PubMed  CAS  Google Scholar 

  120. Kessler KM,Lowenthal DR,Warner H et al: Quinidine elimination in patients with congestive heart failure or poor renal function. N Engl J Med 290: 706–709, 1974.

    PubMed  CAS  Google Scholar 

  121. Drayer DE, Lowenthal DT, Restivo KM et al: Steady State serum levels of qxiinidine and active metabolites in cardiac patients with varying degrees of renal function. Clin Pharmacol Ther 24: 31–39, 1978.

    PubMed  CAS  Google Scholar 

  122. Gibson TP, Lowenthal DT, Nelson HA, Briggs WA: Elimination of procainamide in end stage renal failure. Clin Pharmacol Ther 17: 321–329, 1975.

    PubMed  CAS  Google Scholar 

  123. Gibson TP, Matusik J, Matusik E et al: Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype. Clin Pharmacol Ther 17: 395–399, 1975.

    PubMed  CAS  Google Scholar 

  124. Gibson TP, Matusik EJ, Briggs WA: N-acetylprocainamide levels in patients with ensstage renal failure. Clin Parmacol Ther 19: 206–212, 1975.

    Google Scholar 

  125. Gibson TP, Atkinson AJ Jr, Matusik E et al.: Kinetics of procainamide and n-acetylprocainamide in renal failure. Kidney Int 12: 422–429, 1977.

    PubMed  CAS  Google Scholar 

  126. Stone WJ, Walle T: Massive propranolol metabolite retention during maintenance hemodialysis. Clin Pharmacol Ther 28: 449–467, 1980.

    PubMed  CAS  Google Scholar 

  127. Brogden RN, Heel RC, Speight TM, Avery GS: Metoprolol: A review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 14: 321–348, 1977.

    PubMed  CAS  Google Scholar 

  128. McAinsh J, Holmes BF, Smith S et al: Atenolol kinetics in renal failure. Clin Pharmacol Ther 28: 302–309, 1980.

    PubMed  CAS  Google Scholar 

  129. Johnsson G, Regardh CG: Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. Clin Pharmacokinet 1: 233–263, 1976.

    PubMed  CAS  Google Scholar 

  130. Blair AD, Burgess ED, Maxwell BM, Cutler RE: Sotalol kinetics in renal insufficiency. Clin Pharmacol Ther 29: 457–463, 1981.

    PubMed  CAS  Google Scholar 

  131. Lowenthal DT, Pitone JM, Affrime MB et al: Timolol kinetics in chronic renal insufficiency. Clin Pharmacol Ther 23: 606–615, 1978.

    PubMed  CAS  Google Scholar 

  132. Thomson PD, Melmon KL, Richardson JA et al: Lidocaine pharmacokinetics in advanced heart failure, liver disease and renal failure in humans. Ann Intern Med 78: 499–508, 1973.

    PubMed  CAS  Google Scholar 

  133. Collinsworth KA, Strong JM, Atkinson AJ Jr: Pharmacokinetics and metabolism of lidocaine in patients with renal failure. Clin Pharmacol Ther 18: 59–64, 1975.

    PubMed  CAS  Google Scholar 

  134. Karim A: The pharmacokinetics of norpace. Angiology 26: 85–98, 1975.

    PubMed  CAS  Google Scholar 

  135. Whiting B, Elliott HL: Disopyramide in renal impairment (letter). Lancet 2: 1363, 1977.

    PubMed  CAS  Google Scholar 

  136. Sevka MJ, Matthews SJ, Nightingale CH et al: Disopyramide hemodialysis and kinetics in patients requiring long-term dialysis. Clin Pharmacol Ther 29: 322–326, 1981.

    PubMed  CAS  Google Scholar 

  137. Myhre E, Stenbaek O, Brodwall EK et al: Conjugation of methyldopa in renal failure. Scand J Clin Lab Invest 29: 195–199, 1972.

    PubMed  CAS  Google Scholar 

  138. Stenbaek O, Myhre E, Brodwall EK, Hansen T: Hypotensive effect of methyldopa in renal failure associated with hypertension. Acta Med Scand 191:333–337, 1971.

    Google Scholar 

  139. Reidenberg MM, Drayer D, DeMarco AL et al: Hydralazine elimination in man. Clin Pharmacol Ther 14:970–977, 1973.

    Google Scholar 

  140. Lowenthal DT, Hobbs D, Affrime MB et al: Prazocin kinetics and effectiveness in renal failure. Clin Pharmacol 164. Ther 21: 779–783, 1980.

    Google Scholar 

  141. Dollery CT, Davies DS, Draffan GH et al: Clinical pharmacology and pharmacokinetics of Clonidine. Clin Pharmacol Ther 19: 11–17, 1976.

    PubMed  CAS  Google Scholar 

  142. Lowenthal DT, Mutterperl RE, Zinns G: Bioavailability, pharmacokinetics and pharmacodynamics of minoxidil in chronic renal failure (abst). Clin Pharmacol Ther 21: 109, 1977.

    Google Scholar 

  143. Pearson RM, Breckenridge AM: Renal function, protein binding and pharmacologic response to diazoxide. Br J Clin Pharmacol 3: 169–175, 1976.

    PubMed  CAS  Google Scholar 

  144. Pohl JE, Thurston H: Use of diazoxide in hypertension with renal failure. Br Med J 4: 142–145, 1971.

    PubMed  CAS  Google Scholar 

  145. Appel GB, Neu HC: The nephrotoxicity of antimicrobial agents. N Engl J Med 296:663–670, 722–728, 784–787, 1977.

    Google Scholar 

  146. Aronoff GR, Luft FC: Antimicrobial therapy in patients with impaired renal function. Dial Transplant 8: 14–19, 1979.

    Google Scholar 

  147. Bryan CS, Stone WJ: ‘Comparably massive’ penicillin G therapy in renal failure. Ann Intern Med 82: 189–195, 1975.

    PubMed  CAS  Google Scholar 

  148. Hoffman TA, Cestero R, Bullock WE: Pharmacodynamics of carbenicillin in hepatic and renal failure. Ann Intern Med 73:173–178, 1970.

    Google Scholar 

  149. Pancoast SJ, Jahre JA, Neu HC: Mezlocillin in the therapy of serious infections. Am J Med 67: 747–752, 1979.

    PubMed  CAS  Google Scholar 

  150. Aronoff GR, Sloan RS, Luft FC et al: Mezlocillin pharmacokinetics in renal impairment. Clin Pharmacol Ther 174. 28: 523–528, 1980.

    Google Scholar 

  151. Winston DJ, Murphy W, Young LS et al: Piperacillin therapy for serious bacterial infections. Am J Med 175. 69: 255–261, 1980.

    Google Scholar 

  152. Tune BM, Fravert D: Mechanisms of cephalosporin 176. nephrotoxicity. Kidney Int 18: 591–600, 1980.

    PubMed  CAS  Google Scholar 

  153. Gambertoglio JG, Aziz NS, Lin ET et al: Cefamandole kinetics in uremic patients undergoing hemodialysis. Clin Pharmacol Ther 26: 592–599, 1979.

    PubMed  CAS  Google Scholar 

  154. Mellin H, Welling PG, Madsen PO: Pharmacokinetics of cefamandole in patients with normal and impaired renal function. Antimicrobial Agents Chemother 11: 262–266, 1977.

    CAS  Google Scholar 

  155. Hawkins SS, Alford RH, Stone WJ et al: Ceforanide kinetics in renal insufficiency. Clin Pharmacol Ther 30: 468–474, 1981.

    PubMed  CAS  Google Scholar 

  156. Cutler RE, Blair AD, Kelly MR: Cefadroxil Kinetics in patients with renal insufficiency. Clin Pharmacol Ther 25: 514–521, 1979.

    PubMed  CAS  Google Scholar 

  157. Gartenberg G, Mayers BR, Hirschman SZ, Srulevitch E: Pharmacokinetics of cefactor in patients with stable renal impairment, and patients undergoing haemodialysis. J Antimicrob Chemother 5: 465–470, 1979.

    PubMed  CAS  Google Scholar 

  158. Kaloyanides GJ, Pastoriza-Munoz E: Aminoglycoside nephrotoxicity. Kidney Int 18: 571–582, 1980.

    PubMed  CAS  Google Scholar 

  159. Smith CR, Lipsky JJ, Laskin OL et al: Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 302: 1106–1109, 184. 1980.

    Google Scholar 

  160. Meyer RD: Amikacin. Ann Intern Med 95:328–332, 1981.

    PubMed  CAS  Google Scholar 

  161. Smith CR, Baughman KL, Edwards CQ, et el: Controlled comparison of amikacin and gentamicin. N Engl J Med 296:349–353, 1977.

    Google Scholar 

  162. Trouber PG, Levine DP: Vancomycin ototoxicity in a patient with normal renal function. Ann Intern Med 95: 458–460, 1981.

    Google Scholar 

  163. Geraci JE: Vancomycin. Mayo Clin Proc 52: 631–634, 1977.

    PubMed  CAS  Google Scholar 

  164. Moellering RC, Krogstad DJ, Greenblatt DJ: Vancomycin therapy in patients with impaired renal function. Ann Intern Med 94: 343–346, 1981.

    PubMed  Google Scholar 

  165. Wilson WR: Tetracyclines, chloramphenicol, erythromycin, and clindamycin. Mayo Clin Proc 52: 635–640, 1977.

    PubMed  CAS  Google Scholar 

  166. Whelton A: Tetracyclines in renal insufficiency. Bull NY Acad Med 54: 223–236, 1978.

    CAS  Google Scholar 

  167. Bowersox DW, Winterbauer RH, Stewart GL et al: Isoniazid dosage in patients with renal failure. N Engl J Med 289: 84–87, 1973.

    PubMed  CAS  Google Scholar 

  168. Reidenberg MM, Shear L, Cohen RV: Elimination of isoniazid in patients with impaired renal function. Am Rev Resp Dis 108: 1426–1428, 1973.

    PubMed  CAS  Google Scholar 

  169. Gold CH, Buchanan N, Tringham V et al: Isoniazid pharmacokinetics in patients with chronic renal failure. Clin Neph 10: 365–369, 1976.

    Google Scholar 

  170. Clinicopathologic conference: Generalized seizures following isoniazid therapy for tuberculosis in a patient with uremia. Am J Med 53: 765–774, 1972.

    Google Scholar 

  171. Campese VM, Marzullo F, Schene FP, Coratelli P: Acute renal failure during intermittent rifampin therapy. Nephron 10: 256–261, 1973.

    PubMed  CAS  Google Scholar 

  172. Van Scoy RE: Antituberculosis agents. Mayo Clin Proc 52: 694–700, 1977.

    PubMed  Google Scholar 

  173. Calabresi P, Parks RE: Chemotherapy of neoplastic diseases. Inb: Gilman AG, Goodman LS, Gilman A (eds). The pharmacologic basis of therapeutics. New York, MacMillan, 1980, PP 1249–1313.

    Google Scholar 

  174. Chabner BA, Myers CE, Coleman CN, Johns DG: The clinical pharmacology of antineoplastic agents. N Engl J Med 292:1107–1113, 1159–1168, 1975.

    Google Scholar 

  175. Kroener J, Green M: Cyclophosphamide in renal failure (letter). Am J Med 64: 725–726, 1978.

    PubMed  CAS  Google Scholar 

  176. Wary LH, Lee CS, Majeske BL, Marbury TC: Clearance and recovery calculations in hemodialysis. Clin Pharmacol Ther 29: 365–372, 1981.

    Google Scholar 

  177. Schacht RG, Baldwin DS: Chronic interstitial nephritis and renal failure due to nitrosourea (abst). Kidney Int 14: 661–662, 1978.

    Google Scholar 

  178. Bell R, Sullivan JR, Moon WJ, Hurley TH: High dose methotrexate herapy. Med J Austral 1: 247–249, 1977.

    PubMed  CAS  Google Scholar 

  179. Frei E, Jaffe N, Tattersal MHN et al: New approaches to cancer chemotherapy with methotrexate. N Engl J Med 292: 846–851, 1975.

    PubMed  Google Scholar 

  180. Burke JF, Laucius JF, Brodovsky HS, Soriano RZ: Doxorubian hydrochloride associated renal failure. Arch Intern Med 137: 385–388, 1977.

    PubMed  Google Scholar 

  181. Crooke S, Luft F, Broughton A et al: Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer 39: 1430–1434, 1977.

    PubMed  CAS  Google Scholar 

  182. Blachley JD, Hill JB: Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 95: 628–632, 1981.

    PubMed  CAS  Google Scholar 

  183. Madias NE, Harrington JT: Platinum nephrotoxicity. Am J Med 65: 307–314, 1978.

    PubMed  CAS  Google Scholar 

  184. Vale JA, Rees AJ, Widdop B, Goulding R: Use of charcoal haemoperfusion in the management of severely poisoned patients. Br Med J 1: 5–9, 1975.

    PubMed  CAS  Google Scholar 

  185. Rosenbaum JL, Kramer MS, Raja R:: Resin Hemoperfusion for acute drug intoxication. Arch Intern Med 136: 263–266, 1976.

    PubMed  CAS  Google Scholar 

  186. Hoy W, Schwab G, Freeman RB: Clearance of meprobamate by hemoperfusion over columns of charcoal and amberlite resin. Artif Org 2:395–397, 1978

    CAS  Google Scholar 

  187. Gelfand MC, Winchester JF, Knepshield JH et al: Treatment of severe drug overdose with charcoal hemoperfusion. Trans Am Soc Artif Intern Organs 23: 599–604, 1977

    PubMed  CAS  Google Scholar 

  188. Lynn RI, Honig CL, Jatlow PI, Kliger AS: Resin hemoperfusion in treatment of ethchlorrvynol overdose. Ann Intern Med 91; 549–553, 1979.

    PubMed  CAS  Google Scholar 

  189. Swartz RD, Millman RP, Billi JE et al: Epidemic methanol poisoning: Clinical and biochemical analysis of a ment of severe drug overdosage with charcoal hemoperfurecent episode. Med 60: 373–382, 1981.

    CAS  Google Scholar 

  190. Lorch JA, Garella S: Hemoperfusion to treat intoxications. Ann Intern Med 91: 301–304, 1979.

    PubMed  CAS  Google Scholar 

  191. Dumont C, Rango R: Argument against hemoperfusion in perfusion in treatment of ethchlorvynol overdose. Ann drug overdose. JAMA 242: 1611, 1979.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. William A. Briggs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Franklin D. McDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dale M. Sillix
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Margaret L. MacDougall
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Bernard J. Hanley, Los Angeles, CA, 90033, USA

    Wadi N. Suki M.D. (Professor of Medicine Professor of Physiology and Biophysics Chief) (Professor of Medicine Professor of Physiology and Biophysics Chief)

  2. Division of Nephrology, University of Southern California School of Medicine, Los Angeles, CA, 90033, USA

    Wadi N. Suki M.D. (Professor of Medicine Professor of Physiology and Biophysics Chief) (Professor of Medicine Professor of Physiology and Biophysics Chief)

  3. Renal Section Baylor College of Medicine, The Methodist Hospital, Houston, TX, 77030, USA

    Shaul G. Massry M.D. (Professor of Medicine and Physiology Chief) (Professor of Medicine and Physiology Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Martinus Nijhoff Publishing, Boston / The Hague / Dordrecht / Lancaster

About this chapter

Cite this chapter

Briggs, W.A., McDonald, F.D., Sillix, D.M., MacDougall, M.L. (1984). Use of Drugs in Uremia and Dialysis. In: Suki, W.N., Massry, S.G. (eds) Therapy of Renal Diseases and Related Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3807-9_41

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-3807-9_41

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-3809-3

  • Online ISBN: 978-1-4613-3807-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation